A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 28, 2010

Primary Completion Date

October 12, 2011

Study Completion Date

October 12, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."

DRUG

SRT2104

SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.

Trial Locations (1)

EH16 4SB

GSK Investigational Site, Edinburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Sirtris, a GSK Company

INDUSTRY

NCT01031108 - A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter